IN BRIEF: Hemogenyx Pharma second process qualification run successful

Hemogenyx Pharmaceuticals PLC - London-based biotechnology company - Successfully completes its second process qualification run of the end-to-end process for the manufacture of HEMO-CAR-T cells. The company says it was followed by analytical release tests to verify the quality of the manufactured cells. The run is the second of three identical manufacturing runs required by the US Food and Drug Administration for the submission of an investigational new drug application. The IND application is needed in order to commence phase one clinical trials of HEMO-CAR-T cells.

Current stock price: 1.59 pence, up 8.0% in London on Wednesday afternoon

12-month change: down 18%

By Harvey Dorset, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Hemogenyx Pharmaceuticals